In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
about
Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agentIn vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosisSynergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophiliaIn vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.In vitro susceptibility of Citrobacter species to various antimicrobial agents.Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agentsAeromonas as a human pathogen.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.World-wide development of antibiotic resistance in pneumococci.Norfloxacin: clinical pharmacology and clinical use.Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptideCross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations.Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.Comparison of susceptibility of gentamicin-resistant and -susceptible "Acinetobacter anitratus" to 15 alternative antibiotics.Difloxacin metabolism and pharmacokinetics in humans after single oral dosesIn vitro susceptibility of Acinetobacter species to various antimicrobial agentsPharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures.Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.Comparative in-vitro activity of fourteen antibiotics against clinical isolates of enterococci.Macrolides: problems and promises.In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
P2860
Q23913397-39586861-42C7-437D-BC9F-95CC1356CE49Q28335923-52643011-10F0-416F-8CDD-433D532D63FEQ28369524-048B57CE-5A51-4360-890C-24F44422776CQ35306777-C64F87A6-B7D6-4187-8D29-294E6C595ABAQ35535780-445458F0-9428-49A5-A78B-6761CC6A6F31Q35540611-1F1EDDAD-08E2-476F-A7C2-2E4B120E681BQ37140402-E1E8FC26-C57A-4769-8ED0-EB6C8F60725FQ38614071-8EC365E2-F2F1-4B05-9EED-ED33B347AE7CQ39637667-5BE675B9-3A00-4841-8A98-6493FD73589DQ39673641-06ABDBA8-54FC-40CC-96F4-6BD7F63C751EQ39681144-32E53C1B-63C0-4762-BA8B-75EFCF3C31BBQ39730719-32A581A8-F11F-4200-810F-3E510B654921Q39817448-6A226C78-5F64-42D9-8C70-3C3FC3E05F77Q39819729-108AC4FA-FE1A-491A-9FBF-99C05A4C3C73Q39827664-23F64AC9-3150-4AD1-9AA2-43B5210D8AC6Q39834684-1793EE33-D5BC-4DCF-B375-133ADE90900AQ39834812-06E0C480-313C-4AE0-9F41-E5A8873472A4Q39834860-571D9DD8-A408-4753-B9D1-12CF489A565CQ39834941-60BEC1FC-E801-48B1-A7F4-BBE20DC57014Q39834989-39E0084B-13FE-4433-9E49-7CCCAE8C54EBQ42602439-857760F7-33E1-47C4-A175-FAA562F1A339Q46602051-310DBB04-37E1-4DF3-A372-72F349DC4C56Q54311207-9A2F252D-639D-4FF2-9F89-6722FE63E098Q54388935-91BD4DBB-201B-4C1E-AEA8-2215C68075F1Q54433715-C785AAB9-9C46-4D16-B614-F39C7D8772DF
P2860
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@en
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@nl
type
label
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@en
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@nl
prefLabel
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@en
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@nl
P2093
P2860
P356
P1476
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
@en
P2093
Eliopoulos GM
Moellering AE
Moellering RC Jr
Reiszner E
P2860
P304
P356
10.1128/AAC.28.4.514
P407
P577
1985-10-01T00:00:00Z